Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Cardiology

• Publication date

  2015-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijcard.2014.12.029PMID 25528312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan

  2014cited by this paper
• Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.

  2014cited by this paper
• Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease.

  2014cited by this paper
• All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

  2013influential reference
• Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

  2013cited by this paper
• Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients

  2013cited by this paper
• Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

  2013cited by this paper
• Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

  2012influential reference
• Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.

  2012cited by this paper
• Long-term effects of intensive glucose lowering on cardiovascular outcomes.

  2011cited by this paper
• Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

  2011cited by this paper
• Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients

  2011cited by this paper
• Validation of the national health insurance research database with ischemic stroke cases in Taiwan

  2011cited by this paper
• Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005

  2009cited by this paper
• Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Identification of individuals with CKD from Medicare claims data: a validation study.

  2005cited by this paper
• Epidemiology of cardiovascular complications in type 2 diabetes mellitus

  2003cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes

  2002cited by this paper
• Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease.

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper

• Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management

  2025cites this paper
• Sitagliptin, diabetes mellitus, and heart failure: an in-depth review of sitagliptin therapy and heart failure in patients with diabetes mellitus

  2025cites this paper
• The Benefits of Oral Glucose-Lowering Agents: GLP-1 Receptor Agonists, DPP-4 and SGLT-2 Inhibitors on Myocardial Ischaemia/Reperfusion Injury.

  2024cites this paper
• Association of Renal and Cardiovascular Safety With DPP‐4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease

  2021cites this paper
• Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: a nationwide cohort study of patients with type 2 diabetes.

  2021cites this paper
• Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

  2021cites this paper
• Long‐Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats

  2021cites this paper
• A systematic review considering risk factors for mortality of patients discharged from hospital with a diagnosis of diabetes.

  2020cites this paper
• Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015.

  2020cites this paper
• Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016

  2020cites this paper
• Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease

  2020cites this paper
• Chronic kidney disease–related osteoporosis is associated with incident frailty among patients with diabetic kidney disease: a propensity score–matched cohort study

  2020cites this paper
• Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke

  2019cites this paper
• Predictors of subsequent myocardial infarction, stroke, and death in stable post-myocardial infarction patients: A nationwide cohort study

  2019cites this paper
• Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study

  2019cites this paper
• Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome

  2019cites this paper
• Neuropathy Diabetes Canada Clinical Practice Guidelines Expert Committee

  2018cites this paper
• Impact of dialysis dependence on prognosis in patients with myocardial infarction

  2018cites this paper
• Neuropathy.

  2018cites this paper
• Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes

  2017cites this paper
• Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

  2017cites this paper
• Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

  2017influential citation
• Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study

  2017cites this paper
• No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase‐4 inhibitors vs therapeutic alternatives

  2017cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus

  2017cites this paper
• Insulin Other Hypoglycemic Drugs

  2016cites this paper
• Cardiovascular Effects Of Incretin-Based Antihyperglycemic Drugs Relative To Treatment Alternatives In Older Adults

  2016cites this paper
• Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

  2016cites this paper
• A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.

  2016cites this paper
• Clinical outcomes of drug-eluting stents versus bare-metal stents in patients with cardiogenic shock complicating acute myocardial infarction.

  2016cites this paper
• Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.

  2016cites this paper
• Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study

  2016cites this paper
• Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs

  2016cites this paper
• Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study

  2016cites this paper
• Benefits of Intraaortic Balloon Support for Myocardial Infarction Patients in Severe Cardiogenic Shock Undergoing Coronary Revascularization

  2016influential citation
• Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.

  2016cites this paper
• DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty

  2016cites this paper
• No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.

  2016cites this paper
• Sitagliptin and Risk of Heart Failure in Patients With Type 2 Diabetes: A Meta-Analysis.

  2016cites this paper
• Sitagliptin and other ‘gliptins’– why prescribe them?

  2016cites this paper
• Context-dependent effects of dipeptidyl peptidase 4 inhibitors

  2016cites this paper
• Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

  2016cites this paper
• Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction.

  2016cites this paper
• Clinical Outcomes of Drug-Eluting Stents vs. Bare-Metal Stents in Acute Myocardial Infarction Patients Under Dialysis - A Nationwide Cohort Study.

  2016cites this paper
• Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan

  2015cites this paper
• Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study

  2015cites this paper
• Sitagliptin for Type 2 diabetes: a 2015 update

  2015cites this paper
• L’ÉTUDE CLINIQUE DU MOIS TECOS : confirmation de la sécurité cardiovasculaire de la sitagliptine

  2015influential citation
• Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

  2015cites this paper
• Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors

  2015cites this paper
• Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.

  2015cites this paper
• Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study

  2015cites this paper